Abbonarsi

Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy - 20/12/12

Doi : 10.1016/j.jpeds.2012.05.067 
Michelle A. Farrar, MBBS 1, 2, , Steve Vucic, MBBS, PhD 1, 3, Heather M. Johnston, MBChB 2, Desirée du Sart, MBBS, PhD 4, Matthew C. Kiernan, MBBS, PhD, DSc 1, 5
1 Neurosciences Research Australia, Randwick, Sydney, Australia 
2 Department of Neurology, Sydney Children’s Hospital, School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia 
3 Department of Neurology, Westmead Hospital, Western Clinical School, University of Sydney, Sydney, Australia 
4 Molecular Genetics Laboratory, Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Parkville, Victoria, Australia 
5 Prince of Wales Clinical School, University of New South Wales, Randwick, Sydney, Australia 

Reprint requests: Michelle A. Farrar, MBBS, Neurosciences Research Australia, PO Box 1165, Randwick, NSW 2031, Australia.

Abstract

Objective

To examine the natural history of spinal muscular atrophy (SMA) to gain further insight into the clinical course and pathogenesis.

Study design

Survival pattern, age of onset, and ambulatory status were retrospectively analyzed in 70 patients with SMA with deletions of the survival motor neuron 1 genes that presented to a specialized neuromuscular clinic. The Kaplan-Meier method was used to obtain survival curves. Hammersmith Functional Motor Scale-Expanded and abductor pollicis brevis compound muscle action potential amplitudes were assessed in 25 of the surviving cohort and correlated with survival motor neuron 2 copy number.

Results

Survival probabilities at ages 1, 2, 4, 10, 20, and 40 years were 40%, 25%, 6%, and 0%, respectively, for patients with SMA type 1; 100%, 100%, 97%, 93%, 93%, and 52% for patients with SMA type 2 and all patients with SMA type 3 were alive (age range 7-33 years). There were significant associations between age of onset and long-term outcome, specifically survival in SMA type 1 (P < .01) and Hammersmith Functional Motor Scale-Expanded (P < .0001), and compound muscle action potential (P = .001) in SMA types 2 and 3. Motor function in patients with long-standing SMA reduced over prolonged periods or remained stable. Survival motor neuron 2 copy number related to continuing changes in motor function with age.

Conclusion

The natural history of SMA suggests considerable early loss of motor neurons, with severity related to differences in the number of remaining motor neurons. As the ensuing chronic course in milder phenotypes suggests relative stability of remaining motor neurons, the maximal therapeutic window presents early.

Il testo completo di questo articolo è disponibile in PDF.

Keyword : CMAP, HFMS-E, SMA, SMN, SMN1, SMN2


Mappa


 M.F. received grant support from the National Health and Medical Research Council of Australia (Medical Postgraduate Scholarship, ID568915). S.V. serves on the scientific advisory board for Novartis, Merck Serono Australia, and Bayer Schering Australia, and as a medical consultant for Merck Serono Australia. M.K. serves as Editor in Chief of the Journal of Neurology, Neurosurgery and Psychiatry (BMJ Group). The other authors declare no conflicts of interest.


Crown Copyright © 2013  Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 162 - N° 1

P. 155-159 - gennaio 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus
  • Samer S. El-Kamary, Mohamed Hashem, Doaa A. Saleh, Sayed F. Abdelwahab, Maha Sobhy, Fatma M. Shebl, Michelle D. Shardell, G. Thomas Strickland, Mohamed Tarek Shata
| Articolo seguente Articolo seguente
  • School Attendance in Childhood Cancer Survivors and Their Siblings
  • Amy E. French, Elena Tsangaris, Maru Barrera, Sharon Guger, Robert Brown, Stacey Urbach, Derek Stephens, Paul C. Nathan

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.